Upregulation and Nuclear Recruitment of HDACl in Hormone Refractory Prostate Cancer

Prostate

Volumn 59, Issue 2, 2004, Pages 177-189

  Halkidou, Kalipso ^a   Gaughan, Luke ^a   Cook, Susan ^a   Leung, Hing Y ^a   Neal, David E ^b   Robson, Craig N ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Androgen ablation; Deacetylation; HDAC1; Hormone refractory; Proliferation; Prostate

Indexed keywords

HISTONE DEACETYLASE; PROTEIN P53; TRANSCRIPTION FACTOR;

ANDROGEN METABOLISM; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; ENZYME REGULATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; HDAC1 GENE; HORMONAL CARCINOGENESIS; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; METABOLIC REGULATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REPRESSOR GENE; STATISTICAL SIGNIFICANCE; TRANSCRIPTION REGULATION; XENOGRAFT;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; CELL DIVISION; CELL NUCLEUS; CYTOKINES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 1842631408     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20022     Document Type: Article

References (59)

1. Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, Wingo PA, Jemal A, Feigal EG. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer 2002;94(10):2766-2792.
2. Wingo PA, Cardinez CJ, Landis SH, Greenlee RT, Ries LA, Anderson RN, Thun MJ. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer 2003;97(12 suppl):3133-3275.
3. Cheng L, Slezak J, Bergstralh EJ, Cheville JC, Sweat S, Zincke H, Bostwick DG. Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer 1999;86(4):657-663.
4. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, Trapman J. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 1991;48(2):189-193.
5. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998;20(8):615-626.
6. Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001;262(2):75-83.
7. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996;272(5260):408-411.
8. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000;184(1):1-16.
9. Ng HH, Bird A. Histone deacetylases: Silencers for hire. Trends Biochem Sci 2000;25(3):121-126.
10. Bartl S, Taplick J, Lagger G, Khier H, Kuchler K, Seiser C. Identification of mouse histone deacetylase 1 as a growth factor-inducible gene. Mol Cell Biol 1997;17(9):5033-5043.
11. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002;21(11):2672-2681.
12. Mal A, Sturniolo M, Schiltz RL, Ghosh MK, Harter ML. A role for histone deacetylase HDAC1 in modulating the transcriptional activity of MyoD: Inhibition of the myogenic program. EMBO J 2001;20(7):1739-1753.
13. Swinnen JV, Esquenet M, Heyns W, Rombauts W, Verhoeven G. Androgen regulation of the messenger RNA encoding diazepam-binding inhibitor/acyl-CoA-binding protein in the human prostatic adenocarcinoma cell line LNCaP. Mol Cell Endocrinol 1994;104(2):153-162.
14. Gnanapragasam VJ, Robson CN, Neal DE, Leung HY. Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene 2002;21(33):5069-5080.
15. Krenacs L, Harris CA, Raffeld M, Jaffe ES. Immunohistochemical diagnosis of T-cell lymphomas in paraffin sections. J Cell Pathol 1996;1:125-136.
16. Norton AJ, Jordan S, Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): A simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 1994;173(4):371-379.
17. Bouras T, Southey MC, Venter DJ. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res 2001;61(3):903-907.
18. Wallace W, Schaefer LH, Swedlow JR. A workingperson's guide to deconvolution in light microscopy. Biotechniques 2001;31(5):1076-1082.
19. Shankey TV, Rabinovitch PS, Bagwell B, Bauer KD, Duque RE, Hedley DW, Mayall BH, Wheeless L, Cox C. Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry 1993;14(5):472-477.
20. Bagwell CB, Clark GM, Spyratos F, Chassevent A, Bendahl PO, Stal O, Killander D, Jourdan ML, Romain S, Hunsberger B, Baldetorp B. Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens. Cytometry 2001;46(3):121-135.
21. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, Edgehouse NL, Pretlow TP, Bodner DR, Kursh ED. CWR22: Androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994;54(23):6049-6052.
22. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG. CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56(13):3042-3046.
23. Morsi HM, Leers MP, Radespiel-Troger M, Bjorklund V, Kabarity HE, Nap M, Jager W. Apoptosis, bcl-2 expression, and proliferation in benign and malignant endometrial epithelium: An approach using multiparameter flow cytometry. Gynecol Oncol 2000;77(1):11-17.
24. Rupa JD, de Bruine AP, Gerbers AJ, Leers MP, Nap M, Kessels AG, Schutte B, Arends JW. Simultaneous detection of apoptosis and proliferation in colorectal carcinoma by multiparameter flow cytometry allows separation of high and low-turnover tumors with distinct clinical outcome. Cancer 2003;97(10):2404-2411.
25. van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001;195(5):563-570.
26. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998;18(12):7185-7191.
27. Kramer OH, Gottlicher M, Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 2001;12(7):294-300.
28. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92(15):1210-1216.
29. Weidle UH, Grossmann A. Inhibition of histone deacetylases: A new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res 2000;20(3A):1471-1485.
30. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60(18):5165-5170.
31. Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB, Donehower RC. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 2001;7(10):3047-3055.
32. Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, Goetz A, Felton SA, Burton S, Valone FH, Eckhardt SG. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res 2002;8(7):2142-2148.
33. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8(3):718-728.
34. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, Mancini M, Pelicci PG, Lo Coco F, Nervi C. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001;61(1):2-7.
35. Weiser TS, Ohnmacht GA, Guo ZS, Fischette MR, Chen GA, Hong JA, Nguyen DM, Schrump DS. Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg 2001;71(1):295-301.
36. Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem 2002;277(29):25904-25913.
37. Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 2001;287(3):705-713.
38. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001;92(12):1300-1304.
39. Galasinski SC, Resing KA, Goodrich JA, Ahn NG. Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions. J Biol Chem 2002;277(22):19618-19626.
40. Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000;408(6810):377-381.
41. Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, Brosch G, Wintersberger E, Seiser C. Histone deacetylase 1 can repress transcription by binding to Spl. Mol Cell Biol 1999;19(8):5504-5511.
42. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J 2000;19(4):662-671.
43. Zhou Q, Melkoumian ZK, Lucktong A, Moniwa M, Davie JR, Strobl JS. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J Biol Chem 2000;275(45):35256-35263.
44. Medina V, Edmonds B, Young GP, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): Dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 1997;57(17):3697-3707.
45. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265(28):17174-17179.
46. Suenaga M, Soda H, Oka M, Yamaguchi A, Nakatomi K, Shiozawa K, Kawabata S, Kasai T, Yamada Y, Kamihira S, Tei C, Kohno S. Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. Int J Cancer 2002;97(5):621-625.
47. Fusenig NE, Breitkreutz D, Boukamp P, Tomakidi P, Stark HJ. Differentiation and tumor progression. Recent Results Cancer Res 1995;139:1-19.
48. Brawn PN, Speights VO. The dedifferentiation of metastatic prostate carcinoma. Br J Cancer 1989;59(1):85-88.
49. Brawn P, Kuhl D, Johnson C III, Pandya P, McCord R. Stage Dl prostate carcinoma. The histologic appearance of nodal metastases and its relationship to survival. Cancer 1990;65(3):538-543.
50. Brawn P. Histologic features of metastatic prostate cancer. Hum Pathol 1992;23(3):267-272.
51. Bazinet M, Hamdy SM, Begin LR, Stephenson RA, Fair WR. Prognostic significance of antigenic heterogeneity, Gleason grade, and ploidy of lymph node metastases in patients with prostate cancer. Prostate 1992;20(4):311-326.
52. Isaacs JT. Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol 1997;150(5):1511-1521.
53. Alberti I, Barboro P, Barbesino M, Sanna P, Pisciotta L, Parodi S, Nicolo G, Boccardo F, Galli S, Patrone E, Balbi C. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer. J Cell Biochem 2000;79(3):471-485.
54. Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ. Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 1997;33(2):263-271.
55. van Leenders GJ, Schalken JA. Stem cell differentiation within the human prostate epithelium: Implications for prostate carcinogenesis (Discussion 49-50). BJU Int 2001;88(suppl 2):35-42.
56. van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 2000;80(8):1251-1258.
57. Gil-Diez de Medina S, Salomon L, Colombel M, Abbou CC, Bellot J, Thiery JP, Radvanyi F, Van der Kwast TH, Chopin DK. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum Pathol 1998;29(9):1005-1012.
58. Nagle RB, Ahmann FR, McDaniel KM, Paquin ML, Clark VA, Celniker A. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res 1987;47(1):281-286.
59. Sherwood ER, Berg LA, Mitchell NJ, McNeal JE, Kozlowski JM, Lee C. Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. J Urol 1990;143(1):167-171.